



THE PROMISE OF EMERGENT NANOTECHNOLOGIES FOR IN VIVO APPLICATIONS AND IMPLICATIONS FOR SAFETY AND SECURITY

Anne M. Arnold, Ashley M. Bradley, Karen L. Taylor, Zachary C. Kennedy, and Kristin M. Omberg

Nanotechnology, the multidisciplinary field based on the exploitation of the unique physicochemical properties of nanoparticles (NPs) and nanoscale materials, has opened a new realm of possibilities for biological research and biomedical applications. The development and deployment of mRNA-NP vaccines for COVID-19, for example, may revolutionize vaccines and therapeutics. However, regulatory and ethical frameworks that protect the health and safety of the global community and environment are lagging, particularly for nanotechnology geared toward biological applications (ie, bionanotechnology). In this article, while not comprehensive, we attempt to illustrate the breadth and promise of bionanotechnology developments, and how they may present future safety and security challenges. Specifically, we address current advancements to streamline the development of engineered NPs for in vivo applications and provide discussion on nano–bio interactions, NP in vivo delivery, nanoenhancement of human performance, nanomedicine, and the impacts of NPs on human health and the environment.

Keywords: Dual-use science, Biotech industry, Code of conduct, Biosafety protection, Nanoparticles

INTRODUCTION

THE CONVERGENCE OF nanomaterials and technology, inspired by the unique physicochemical properties of nanoparticles (NPs) and materials, has produced the multidisciplinary field of nanotechnology. NPs and nanomaterials range from 1 to 100 nm in at least 1 dimension but may be longer in the other 2.^{1,2} They can be produced naturally (eg, by degradation, weathering, or human activities such as burning fossil fuels) or synthetically; synthetic NPs and nanomaterials are often referred to as “engineered.”²

Nanomaterials research and development is driven globally by major players, including China, Europe, Russia,

and the United States.^{3–6} In 2000, the United States created a government framework known as the National Nanotechnology Initiative (NNI) to seed the commercialization of nanotechnology.^{5,7} Since its inception, more than US\$35 billion has been invested^{5,8} and NNI has served as global inspiration for other nations.⁹ For example, the European Union made a notable investment (US\$1.35 billion) in the Graphene Flagship project.^{3,10,11} Likewise, Russia invested US\$2.7 billion as of 2018, with a US\$190 million net return; its investments are managed by the RUSNANO group,¹² an entity that “implements state policy for the development of the nanoindustry in Russia, acting as a co-investor in nanotechnology projects, which

Anne M. Arnold, PhD, is a Materials Scientist; Ashley M. Bradley is a Biomedical Scientist; Zachary C. Kennedy, PhD, is a Materials Scientist; and Kristin M. Omberg, PhD, is Group Leader; all at the National Security Directorate, Pacific Northwest National Laboratory, Richland, WA. Karen L. Taylor, MPH, is a Senior Technical Advisor, National Security Directorate, Pacific Northwest National Laboratory, Seattle, WA.

© Anne M. Arnold *et al.*, 2022; Published by Mary Ann Liebert, Inc. This Open Access article is distributed under the terms of the Creative Commons License (<http://creativecommons.org/licenses/by/4.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.

have substantial economic or social potential.”¹³ The sum of nanotechnology investments in China are less clear,^{14,15} although between 2012 and 2017, China’s Strategic Pioneering Program on Nanotechnology reportedly invested more than US\$152 million.¹⁴

The increase in research and development funding has fueled extensive global scientific growth: a search for “nanotechnology” in Google Scholar displays over 1 million publications and patents in the last 2 decades. Nanotechnology publications and patents are being collated into publicly available databases to foster collaboration and increase transparency. Journals such as *Data in Brief*¹⁶ and *Chemical Data Collections*¹⁷ have created multiple open access repositories for raw experimental data. In addition, public databases (eg, NBI Knowledgebase,^{18,19} caNanoLab,^{18,20} The Nanodatabase,²¹ and the recently retired Nanomaterial Registry^{18,22}) have been launched to share protocols, data, and literature among a diverse audience.¹⁸

The global community has recognized the need for an approach to nanotechnology regulation to supervise the ethical implementation of NPs and protect human health and the environment.²³ However, relevant agencies, organizations, councils, and strategies are not globally cooperative and substantial gaps remain within existing national and international policy frameworks^{24–26} (Table 1). Current NP regulations typically use preexisting standards for microscale and macroscale materials. However, these may not be applicable to NPs^{57–60} since the physicochemical properties that make nanomaterials useful also make it difficult to extrapolate long-term effects on human and environmental health.¹ Additional barriers to NP oversight include disagreements between regulatory committees on the definition of NPs,⁶¹ nanomaterial diversity and applications,^{62,63} and limitations in mass production of NPs that result in poor quality control.⁶⁴

Due to the complexity of the problem, the overlap of nanotechnology with biological safety and security is easy to overlook. But nanotechnology is enabling new areas with the potential to directly impact human health, such as platform-based therapeutics and human performance enhancement, which makes it imperative that we consider these gaps in our understanding and regulations. In many ways, the issues associated with the increasing use of nanotechnology are similar to those raised by the increasing use of synthetic biology.^{65,66} Due to this, and the overlap of safety and security issues, the health security community should be aware of and proactive in addressing these concerns.

The following review is intended to provide a high-level overview of advances in relevant nanobiotechnology (ie, nanotechnology used for biomedical applications) research and development and offer insight into potential hazards that may arise. Given the breadth of current research and development, it is not intended to provide a comprehensive review of nanoscale science but focuses specifically on the promise and concerns associated with NPs for in vivo use,

and outlines concerns with respect to biological safety and security. In this review, we refer to NP biological safety (or biosafety) as the risks to human and environmental health associated with unintentional NP exposure⁶⁷; further, we describe NP biological security (or biosecurity) as the risks to human and environmental health caused by the nefarious application of nano-based technologies.^{65,68–70}

NANOMATERIALS ARE IDEALLY SUITED FOR BIOLOGICAL APPLICATIONS

NPs have broadly heterogeneous physicochemical properties such as size, shape, charge, porosity, chemical composition, surface morphology, and stability. They are often classified by their material composition with main classes including carbon-based, lipid-based, polymeric, semiconductor, metallic, and ceramic. This breadth of properties, combined with their small size, makes NPs ideally suited for biological applications (Table 2). NPs are significantly smaller than the average eukaryotic cell and can pass through biological barriers such as cell membranes, tissues, and organs. This is beneficial for applications such as bioimaging, gene therapy, and drug delivery.⁹⁹

NANOPARTICLES HAVE TUNABLE PHYSICOCHEMICAL PROPERTIES

NP properties can be manipulated and tuned for a desired function, such as the ability to carry and release a therapeutic chemical payload, fluoresce at a particular wavelength, or cross the blood–brain barrier, by utilizing typical design processes.^{100–102} The development of synthetic nanomaterials, especially those intended for in vivo use, is often lengthy¹⁰³; however, recent advances may reduce the timescale via sophisticated production and screening techniques. For instance, an autonomous platform that leverages Darwinian evolution has demonstrated great utility in the synthesis of gold NPs with programmable shapes. The platform uses a robotic component to synthesize NPs, with spectroscopic analysis to ascertain shape. The spectroscopic analysis uses a genetic algorithm that makes autonomous decisions for the optimization of synthetic conditions to generate shapes of interest. The platform proceeds through cycles of evolution until the desired NP shape is achieved.¹⁰⁴

High-throughput screening using modeling,¹⁸ dynamic evolution,¹⁰⁵ and libraries^{103,106,107} are also being investigated. In 2019, researchers at Northwestern University and the Air Force Research Laboratory reported their method to screen megalibraries of millions of NPs with distinct composition and size.¹⁰³ Gold and silver NPs were formulated into inks that were deposited onto a substrate array using a spray lithography technique. The resulting arrays were used as nanoreactors to catalyze the growth of carbon nanotubes. The catalytic activity of the nanoreactors was

Table 1. Collaborative Global and US Nanoparticle Oversight Frameworks

<i>International</i>				
<i>Organization/Council</i>	<i>Committee/Act/Strategy</i>	<i>Responsibilities/ Goals</i>	<i>Participating Countries</i>	<i>References</i>
Canada-US Regulatory Cooperation Council		Develop consistent policies on NP oversight	Canada, United States	27,28
Organisation for Economic Cooperation and Development	OECD Working Party	Understand properties and risks of NPs	Australia, Austria, Belgium, Canada, Chile, Colombia, Costa Rica, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Republic of Korea, Latvia, Lithuania, Luxembourg, Mexico, Netherlands, New Zealand, Norway, Poland, Portugal, Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, United Kingdom, United States	27-29
International Organization for Standardization	Technical Committee 229	Establish NP standards	Great Britain, Switzerland ^a	27,30
ASTM International	Committee E56 (Nanotechnology)	Establish NP standards	Canada, India, Italy, United States	31,32
Federal Ministry for Economic Affairs and Climate Action	Bundesanstalt für Materialforschung und -prüfung	Establish NP standards	Germany	33
International Electrotechnical Commission	Technical Committee 113	Standardize nano-based electrotechnical products	Germany, Korea ^a	34,35
Institute of Electrical and Electronics Engineers	Nanotechnology Council	Coordinate and advance nanotechnology	United States ^a	36,37
<i>United States</i>				
<i>Organization</i>	<i>Acts/Strategies</i>		<i>Responsibilities/ Goals</i>	<i>References</i>
American National Standards Institute Nanotechnology Standards Panel	ANSI-NSP Nanotechnology Standards Database		Establish NP standards	38

(continued)

Table 1. (Continued)

<i>United States</i>			
<i>Organization</i>	<i>Acts/Strategies</i>	<i>Responsibilities/ Goals</i>	<i>References</i>
US Environmental Protection Agency	Nanomaterial Research Strategy	Study NPs that pose human and environmental risks	39,40
	Toxic Substances and Control Act	Review safety of new chemicals	39,41,42
	Safe Drinking Water Act	Regulate NPs materials in potable water supplies	42,43
	Federal Insecticide, Fungicide, and Rodenticide Act	Oversee NPs materials used as pesticides	42,43
	Comprehensive Environmental Response, Compensation, and Liability Act	Provide "Superfunds" to remediate hazardous orphan sites	42,44
	Resource Conservation and Recovery Act	Control hazardous waste from inception to grave	42,46
	Clean Water Act	Regulate emissions of materials into surface waters	42,47
	Clean Air Act	Regulate air emission of materials into air	42,48
	Nanotechnology Task Force	Determine regulatory approaches for nano-based products	49
	Center for Drug Evaluation and Research; Center for Biologics Evaluation and Research; Center for Devices and Radiological Health Federal	Regulate nano-based therapies, products, and devices	28,50-52
US Food and Drug Administration			
US National Institute for Occupational Safety and Health Administration	NIOSH Nanotechnology Research Center	Lead the health and safety initiative for nanotechnology	53

^aDenotes countries represented by the committee and council members, where some positions are elected or appointed terms (as of August 2022). The International Organization for Standardization and the International Electrotechnical Commission have members in 167⁵⁴ and 88 countries,⁵⁵ respectively, while the Institute of Electrical and Electronics Engineers has chapters in more than 14 countries (as of August 2022).⁵⁶ Note that this is not a comprehensive list of the international or US nanotechnology oversight frameworks. Abbreviations: ANSI, American National Standards Institute; IEC, International Electrotechnical Commission; NIOSH, National Institute for Occupational Safety and Health; NP, nanoparticle; NSP, Nanotechnology Standards Panel.

Table 2. Applications of Nanoparticles for In Vivo Use

<i>Nanoparticles</i>	<i>Size (nm)</i>	<i>Applications</i>	<i>References</i>
Carbon-based Fullerenes, nanotubes, graphene, carbon black	0.7-300	Biosensing, imaging and diagnostics, drug and gene delivery, antivirals, antimicrobial treatment, tissue engineering, therapeutics	70-75
Ceramic-based Silica, alumina, hydroxyapatite	<50	Imaging, drug delivery, catalysis, tissue engineering	76-79
Metal Gold, silver, iron, cobalt nanoparticles	1-200	Drug delivery, biosensing/imaging, therapeutics, biomedical enhancement, antivirals, antimicrobial treatments, antifungal therapies	80-84
Semiconductor Quantum dots, cadmium-telluride, indium phosphide	2-50	Imaging, biosensors	85
Polymeric Chitosan, dendrimers	<15	Imaging and diagnostics, biosensing, therapeutics, drug delivery, tissue engineering, antimicrobial treatments	86-91
Lipid Micelles, liposomes	10-500	Drug and gene delivery, imaging	92-96
Janus ^a	0.7-500	Drug and gene delivery, bioimaging and sensing, tissue engineering	97,98

^aSignifies that Janus particles can be a combination of any chemical compositions listed above.

screened in a high-throughput fashion using Raman spectroscopy, enabling researchers to identify NPs with optimal catalytic activity based on the composition, size, and spatial distribution of NPs.¹⁰³ High-throughput screening methods have been investigated for optimizing lipid or polymer nanoparticles for therapeutic delivery of proteins, oligonucleotides, small interfering RNA (siRNA), and messenger RNA (mRNA). These methods will ultimately reduce the time required to develop NP-stabilized therapeutics, such as mRNA and protein vaccines.

NANOPARTICLE PROPERTIES DICTATE IN VIVO LIFECYCLE

The physicochemical properties of NPs govern in vivo delivery, biodistribution, metabolism, and clearance, and dictate possible therapeutic applications.¹⁰⁸ There are numerous reviews that evaluate how the physicochemical properties of nanomaterials influence nano-bio interactions.¹⁰⁸⁻¹¹⁰ Delivery routes into the body for NPs are comparable to traditional routes: parenteral and ocular injections, skin absorption, inhalation, and oral delivery (Figure 1A).^{108,111-113} NP distribution within the body, or biodistribution, can be accomplished using passive or active delivery. Passive biodistribution relies on undirected (passive) delivery to the target.^{108,114} It can be enhanced by cloaking the material (eg, coating NPs with polyethylene glycol, also known as PEG)¹¹⁵ to prevent clearance from the body. Active biodistribution methods use targeting mechanisms (eg, carbohydrates or antibodies) to preferentially direct NPs to specific sites (Figure 1).^{114,116}

Metabolism and clearance of NPs is not completely understood, but is known to be facilitated by the kidneys, liver, mucosa, and so on.^{108,113} The ability of NPs to stabilize molecules is attractive for therapeutic delivery and in vivo applications; however, some NPs appear to persist indefinitely through encapsulation in tissues.^{113,117,118} As in vivo monitoring methods evolve, a better understanding of metabolism and clearance will be essential to enable efficient targeted distribution, and to ensure biosafety and biosecurity.

IN VIVO NANOTECHNOLOGY HOLDS PROMISE AND POTENTIAL CONCERNS

Adoption of nano-based products for in vivo use has been slowed by the difficulty of assuring long-term safety. To date, long-term compatibility studies on the metabolism of NPs are sparse, stemming from issues with NP production and detection.^{108,119} Precise control of NP production is a challenge, resulting in NPs with heterogeneous physicochemical properties.¹⁰⁸ The range of properties complicates biocompatibility studies because different combinations of NPs in a payload could produce vastly different behavior in vivo. Further, traditional methods to study the metabolism of drugs are not sufficient to analyze the metabolic cycle of NPs. Carbon-based NPs, although attractive for in vivo applications, are arduous to differentiate from the carbon-rich environment of the surrounding tissue, complicating the study of biodistribution, metabolism, and clearance. In addition, nanomaterials often persist much longer than in vitro cell culture experiments and the lifetimes of model organisms, so full clearance from the model system may not be observed.¹¹⁹




Figure 1. Overview of in vivo (A) administration routes of nanoparticles and (B) biodistribution strategies of nanoparticles (ie, passive and targeted delivery) using coatings. Note that passive delivery strategies demonstrated here rely on stealth coatings to bypass in vivo clearance mechanisms to increase circulation time. Abbreviation: NP, nanoparticle.

Nanoparticle Technology to Advance Treatment of Human Disease

Nanomaterial development for in vivo applications has already generated sophisticated technology, such as NP-stabilized mRNA and protein vaccines for COVID-19. NPs have also been applied in research settings to facilitate genomic editing, alter drug potency, and manipulate the immune response.^{1,2} Here, we intend to highlight some interesting current and future nano-based technologies for nanomedicine, but this discussion is not intended to provide a comprehensive list of technologies, which are covered in other reviews.

Nanoparticles Can Enhance the Precision of Genomic Editing

Genomic editing offers the promise of a permanent solution to disease or disability as an alternative to surgery or medication. However, some clinical applications have been hindered by inefficient in vivo delivery of the gene editing machinery. Gene editing machinery, such as Clus-

tered Regularly Interspaced Palindromic Repeats (CRISPR), consists of a large protein and nucleic acid component, neither of which readily cross cell membranes.¹²⁰⁻¹²³ Because NPs readily cross cell membranes, researchers have begun to use NPs to deliver gene editing constituents with greater efficacy.

Several comprehensive reviews detail the state of the art of NP-mediated gene editing.¹²³⁻¹²⁶ To briefly summarize, lipid-, polymeric-, and gold-based NPs are the most widely studied in vivo CRISPR delivery systems. Targeted delivery strategies have proven to be effective, and in some cases, have been designed so that stimuli (eg, magnetic fields) trigger the release of the CRISPR payload.¹²⁴

NP-CRISPR systems have been designed to target specific cell-types, tissues, and organs in animal models.¹²⁷ Strategies using NP-CRISPR systems have been developed to understand disease and improve treatment methods for genetic disorders,¹²⁸ certain cancers,^{128,129} and other conditions. An interesting example of recent achievements in the NP-mediated delivery of CRISPR is a promising intrauterine gene editing method to treat mice that model

human β -thalassemia (a blood disorder). The study demonstrated that gene editing using poly(lactic-co-glycolic acid) NPs encapsulating therapeutic payloads could treat disease even before birth.¹²⁷

Nanoparticles Can Enhance or Decrease Drug Potency

Improving drug delivery systems via NPs is a major area of research. Multitudes of studies have demonstrated the use of NPs for superior, targeted delivery of therapeutics to enhance drug potency; the diversity of NPs used for therapeutic delivery is too extensive to summarize in a review, but include NP classes such as carbon-based, lipid-based, polymeric, and ceramic.¹²⁸⁻¹³⁵

One of the more interesting areas of nanobiotechnology drug delivery may be the use of NPs that can cross the blood–brain barrier, an inherently difficult endeavor. Most research in this area has focused on using polymeric or magnetic NPs to translocate therapeutics into the brain¹³⁶⁻¹⁴² for greater efficacy in treating neurodegenerative diseases.¹⁴⁰⁻¹⁴² The ability of NPs to cross the blood–brain barrier could revolutionize brain imaging and treatment for diseases like Alzheimer’s disease and glioblastoma. However, the development of NPs to circumvent a relatively impermeable biological barrier raises significant peripheral concerns.

Nanoparticles Can Be Used to Modulate Immune Response

NPs can be engineered to avoid recognition from the immune system or to directly influence an immune response.^{143,144} For example, researchers have identified a way to slow the response of macrophages to prevent rapid clearance of foreign, polystyrene nanobeads.¹⁴⁵ Tagging the NPs with peptides recognized by phagocytes as “self” allowed the NPs to evade immune system and exhibit greater persistence.

The NVX-CoV2373 vaccine pioneered by Novavax for COVID-19 was developed using a proprietary NP-mediated delivery system known as Matrix-M to enhance the immune response.^{146,147} These types of immune system modulation could ultimately be used to enhance drug delivery efficiency and imaging.

“Switchable” Nanoparticles

Numerous researchers have been investigating possibilities for “switching” the activity of an NP on or off in vivo. Methods that induce an NP to switch behavior between active and inactive states have been developed using intrinsic or extrinsic stimuli. Intrinsic switching methods include changes in internal homeostasis such as variations in pH, osmolarity, permeability, and enzymatic activity.¹⁴⁸ Extrinsic switching can be achieved by thermal regulation, ultraviolet radiation, ultrasounds, or proximity to a magnetic source.¹⁴⁹ Switching is an attractive feature for therapeutics but raises concerns, including unintended switching or malicious switch “hacking.”

Nanoparticle-Enabled Enhancement of Human Performance

Due to their tunable properties, NPs have been used to enhance chemical reactions and physical properties of materials in laboratory settings for decades. Their ability to cross biological membranes makes them equally promising for human performance enhancement. Researchers have been using NPs to enhance human senses and initiate cellular actions with great success. In an earlier section, we also discussed advances in “switching” nanoparticle activity, which may ultimately enable temporary or reversible enhancement.

Nanoparticles Can Facilitate Physiological Enhancements

Enhancing or repairing damaged human senses (ie, smell, taste, touch, sight, hearing) is an active area of research. Multiple groups are investigating the use of NPs to enhance or repair vision. One set of researchers successfully imparted “night vision” to mice by injecting engineered NPs into the eye, where they bound to the photoreceptor cells in the retina. In vivo, the bound NPs acted as self-powered antennae that converted infrared light into perceptible vision with no impact upon day vision (Figure 2A).¹⁵⁰ In 2018, a team at Bar-Ilan University reported nanomaterial-mediated vision repair: drops directly applied to the eye that repair near- and farsighted vision by altering the corneal refractive index, creating an alternative, possibly permanent, method to replace glasses, contact lenses, or surgery.¹⁵¹

NPs are also being used to enhance hearing. A collaborative group at 2 academic universities developed a bionic ear with superior auditory sensing (Figure 2B).¹⁵² The researchers 3D-printed the ear using a cell- and conductive NP-laden hydrogel integrated with electrodes. The ear was able to detect radio frequencies well outside the normal range of human hearing. The team was also able to create complementary ears (right and left) that cooperated to listen to audible music. The bionic ears, while a proof-of-concept demonstration, could be used in the future for organ replacement or to enhance the range of auditory communication.

Physiological enhancements using NPs are not limited to the senses. NPs have been used to promote muscle recovery in in vivo animal models¹⁵³⁻¹⁵⁵ and enhance existing muscle function in vitro.¹⁵⁶ Muscle recovery studies in mice have typically focused on using NPs as carriers and delivery systems for therapeutics that induce muscle repair such as mRNA,¹⁵³ cytokines,¹⁵⁴ and growth factors.¹⁵⁵ However, a team of researchers used an in vitro muscle cell line to enhance muscle function using the intrinsic properties of gold nanoshells (NPs with a silica core coated in a thin layer of gold). The team showed that exposing nanoshell-doped muscle cells to near-infrared light (ie, heat) within physiological temperature ranges induced muscle contraction (Figure 2C). This wireless stimulation of muscle cells used a unique mechanism distinct from natural muscle contraction.¹⁵⁶




Figure 2. Nanomaterial studies that have enhanced physiological performance. (A) An engineered nanoparticle (pbUCNP) that imparts night vision in mice. Representation of pbUCNP injection into the eye, where it binds with photoreceptor cells in the retina. pbUCNP serves as a self-powered antenna that can be stimulated at 535 nm (day vision) and 980 nm (night vision). Reprinted with permission from Ma Y.¹⁵⁰ (B) A 3D printed bionic ear composed of a hydrogel laden with cells and conductive nanoparticles coupled to electrodes for auditory sensing. The bionic ear demonstrated enhanced auditory sensing when compared with human hearing. Reprinted with permission from the American Chemical Society.¹⁵² (C) In vitro study with muscle cells doped with gold nanoshells (ie, NPs consisting of silica coated with a thin layer of gold), where the NPs induced muscle contraction with an externally applied heat source. Reprinted with permission from the American Chemical Society.¹⁵⁶ Abbreviations: NP, nanoparticle; pbUCNP, photoreceptor-binding upconversion nanoparticle.

Nanoparticles May Be Developed to Facilitate Cognitive Enhancements

The development and implementation of NPs that enhance cognitive function has yet to be realized. However, recent advances on the micro- and macro-level with neural-machine interfacing provide the building blocks necessary to develop this technology on the nanoscale. A noninvasive brain-computer interface to control a robotic arm was developed by teams at 2 universities.¹⁵⁷ A US-based company, Neuralink, is at the forefront of implementing implantable, intracortical microelectrodes that provide an interface between the human brain and technology.^{158,159} Utilization of intracortical microelectrodes may ultimately provide thought-initiated access and control of computers and mobile devices, and possibly expand cognitive function by accessing underutilized areas of the brain.¹⁵⁸

Nanobiotechnology Raises Biosafety and Biosecurity, Ethical, and Environmental Quandaries

Nanobiotechnology is enabling advances in genome editing and therapeutics stabilization and delivery and may one day enable modulation of the immune response and human performance enhancement. These are enormous scientific accomplishments; however, these technologies generate a litany of biological safety and security concerns as well as ethical issues. The scientific community is still grappling with the biosafety, biosecurity, ethics, and legality of CRISPR-enabled performance enhancement and “bio-hacking.” For example, many nations are apprehensive of human genome editing and ban its practice^{160,161}; yet in 2018, a Chinese scientist announced the birth of 2 babies

whose genomes were edited to be more resistant to HIV infection.¹⁶¹⁻¹⁶³ In response, the World Health Organization called for development of an international governance framework for human genome editing.¹⁶⁴ NP-enabled human biohacking brings a new aspect to this type of problem. Considering the breadth and complexity of the ethical concerns regarding in vivo use of NPs, we refer readers to the *NanoEthics* journal,¹⁶⁵ which provides a multidisciplinary platform to discuss the ethical and social implications of NP technologies.

Nanobiotechnology Raises Biological Safety and Security Concerns

NPs have intrinsic properties that enable them to pass through biological barriers including cell membranes, organs, and the blood–brain barrier, and many researchers are working to enhance and direct these properties. While this work will enable advanced biomedical applications, it significantly increases biosafety concerns (Figure 3). Researchers handling NP-enhanced therapeutics should consider short-term and long-term effects of exposure to both the individual and combined materials. The mechanisms by which NPs are removed from the body are not completely understood; but, because NPs are often picked up by phagocytic cells, they have been postulated to produce unintended effects such as immunostimulation or immunosuppression, which could result in allergic reactions, chronic inflammation, and potential disease.¹⁶⁶

NPs that facilitate delivery of therapeutics across the blood–brain barrier also present unique biosafety security concerns. The molecular pathways that dictate cognition and memory formation are not completely understood, but research has implicated that small molecules (eg, formaldehyde) influence these pathways.^{167,168} Human health could be negatively impacted by unintentional or nefarious

exposure to chemicals that inhibit memory¹⁶⁷ or sequester chemicals needed for memory formation.^{168,169} NPs may also increase the permeability of the blood–brain barrier, which is associated with neurological disorders.

The ability to manipulate drug potency with NPs raises biological safety and security concerns. Drug delivery methods developed for therapeutics, such as pain relief,¹⁷⁰⁻¹⁷² ultimately could be adapted to trigger side effects or increase potency of commonly abused substances such as narcotics and opioids. With the drug epidemic at an all-time high, NP technology could be used to increase addiction numbers and the severity of a user's dependency, resulting in more overdose-related deaths. NPs could also be used to alter over-the-counter products to increase potency and the possibility of side effects.

Novel technologies are vulnerable to ethical asymmetries and unintended use, creating concerns that nanobiotechnology could be used to cause deliberate damage to human health. The capability to hack human health-related technology has already been demonstrated on the macro- and microscale. “White hacker” proofs by government agencies and academic institutions of medical devices such as magnetic resonance imaging (MRI) machines¹⁷³ and implantables (eg, pacemakers, insulin pumps,¹⁷³ and neurostimulators)¹⁷⁴ enabled with wireless technology have created disquiet in the medical and security communities. Deliberate “hacking” of NPs that can be switched by thermal regulation, ultraviolet radiation, ultrasounds, or proximity to a magnetic source could be used to activate or deactivate a critical medical function. These types of biosecurity risks will continue to increase as NP-enabled medical technologies come to market.

Nanobiotechnology Raises Ethical Concerns

Numerous researchers have raised ethical issues associated with in vivo nanobiotechnology. In 2019, a special edition of the *AMA Journal of Ethics* explored a variety of issues associated with nanomedicine, ranging from helping patients understand the unknowns associated with NP-enabled medicines to identifying violations of individual privacy (eg, use of nanomedicine to track prescription drug compliance).¹⁷⁵ More recently, the concentrated distribution of NP-stabilized COVID-19 vaccines in wealthy countries has been questioned.¹⁷⁶ Like any advanced technology, nanobiotechnology has the potential to exacerbate socioeconomic imbalances. If used nefariously or to enhance human performance, it might also create significant geopolitical or military power imbalances (Figure 3).

Nanobiotechnology Raises Environmental Concerns

NPs are common constituents in cosmetic, electronic,¹⁷⁷ optic, automotive,¹⁷⁸ wound dressing,^{176,179} surgical equipment,¹⁷⁹ and food products.¹⁸⁰ As a result, they are commonly distributed throughout the environment. The extensive use of NPs in consumer goods raises concerns about mobility, accumulation, and persistence of




Figure 3. Ethical, safety and security, and environmental concerns arising from NP-mediated physiological or cognitive enhancements and NP-mediated manipulation of genetics, drugs, and the immune system. Abbreviation: NP, nanoparticle.

nanomaterials in the environment (Figure 3).¹⁷⁷ These concerns will be exacerbated by the use of NPs in in vivo applications.

Sunscreen has become a major source of unintentional NP pollution. Sunscreen contains titanium dioxide (TiO₂) and zinc oxide (ZnO) NPs that reflect, scatter, and/or absorb ultraviolet rays.¹⁸¹ TiO₂ and ZnO are considered safe for topical use¹⁸² because they are not soluble and do not absorb through the skin. However, the increasing use of NPs in sunscreens has resulted in the distribution and accumulation of TiO₂ and ZnO in water and soils.¹⁸³ While TiO₂ and ZnO are considered safe for topical usage, chronic exposure to animals through inhalation and ingestion causes an onset of health issues that can lead to aggregation into tissues.^{184,185} TiO₂ particles have been shown to cause oxidative stress that damages brain cells in model organisms.

In part due to their ubiquity and ease of production, ZnO and TiO₂ NPs also are being considered for in vivo applications. There is great interest in using TiO₂ as a photosensitizer for photodynamic therapy for diseases ranging from cancer to psoriasis.¹⁸⁶ ZnO is being considered as an antitumor therapeutic, although the mechanism of toxicity in tumor cells is not well understood.¹⁸⁷ While in vivo applications of these NPs are unlikely to drive pollution compared with sunscreen, these uses highlight both growing interest and the uncertainties associated with environmental accumulation of biologically active NPs.

Silver NPs have a long history of use for their biological activity, specifically their antimicrobial properties, and are in widespread use in products^{185,186} such as water filters,¹⁸⁵ cosmetics,^{188,189} toothpaste,¹⁸⁸ wound dressings, and surgical instruments.¹⁸⁹ To date, silver NP safety has not been properly established,¹⁸⁸ although an increasing number of studies have emphasized their toxicity¹⁸⁹ and associated silver NP exposure with health risks¹⁸⁸⁻¹⁹¹ such as encapsulation in lung tissue,¹⁸⁹ oxidative stress, DNA damage,¹⁹¹ inflammation,¹⁸⁹ and cognitive impairment.¹⁸⁸

The increasing risk of engineered nanomaterial accumulation in the environment and unintended exposure has galvanized policymakers to begin the inception of regulatory NP policies. France banned the use of TiO₂ in food products beginning in January 2020.¹⁹² In October 2021, the European Commission amended certification of certain TiO₂ powders as a Category 2 suspected carcinogen.¹⁹³ The Canadian General Standards Board implemented a more comprehensive approach to NP regulations, banning all NPs from the production and preparation processes of organic food.¹⁹⁴ These policies do not address other families of nanomaterials or other consumer products.⁵⁹

Ultimately, NP environmental pollution or deliberate contamination are also biosecurity concerns. Because NPs can aggregate in water and sediment, aquatic organisms used as food sources may accumulate contaminants, creating short- and long-term deleterious effects on the food

chain and ecosystem. Accidental or deliberate environmental dispersal of NPs could also render areas unsafe for agricultural use.

CONCLUSION

The convergence of nanomaterials, technology, and biology holds tremendous promise. NPs enable superior strategies compared with traditional microscale materials for many biomedical applications, including gene therapy, drug delivery, and bioimaging/biosensing. Many of the same properties that make nanomaterials excellent candidates for in vivo use also raise biological safety and security concerns and could be intentionally exploited for harmful activities. Because of this potential for harm, awareness of concerns and threats arising from nano-based research is becoming increasingly important.

The recent widespread use of NP-stabilized vaccines for COVID-19 is just one example of the utility of nanobiotechnology to transform human health. However, the long-term biological safety and security effects of these technologies should be an active area of consideration, specifically in the realm of policy regulation. Unfortunately, regulation of nano-based technologies is not sufficient. The policy framework is often segmented by locale (eg, policies in the United States differ greatly from those in European countries), and within these segmented frameworks, there is a lack of interagency overlap to address the regulation of NPs. For example, in the United States, nanomedicines are regulated by the US Food and Drug Administration, but the persistence of these therapies and their effects on the environment is often not considered or regulated by the US Environmental Protection Agency. Thus, we suggest the development of a more cooperative, global policy framework that considers the heterogeneity and persistence of NP-based technologies.

The development of a global policy framework for nanobiotechnology will not be an easy feat and requires a proactive approach to continually identify short- and long-term biosafety and biosecurity risks associated with NP usage. The synthetic biology community has developed a unique approach to identify biological safety and security issues associated with new technologies using the International Genetically Engineered Machine (iGEM) competition. iGEM is set up broadly to cover synthetic biology as a whole and is governed by an experienced panel of judges and coaches and defined rules. Medical- and pharmaceutical-focused nanobiotechnology is a smaller field than what iGEM encompasses, and therefore adoption of a similar approach would need to be scaled and focused to be most effective.

REFERENCES

1. Resnik DB. How should engineered nanomaterials be regulated for public and environmental health? *AMA J Ethics*. 2019;21(4):363-369.

2. Singh AK. Structure, synthesis, and application of nanoparticles. In: Singh AK, ed. *Engineered Nanoparticles*. Boston: Academic Press; 2016:19-76.
3. Jackman JA, Cho DJ, Lee J, et al. Nanotechnology education for the global world: training the leaders of tomorrow. *ACS Nano*. 2016;10(6):5595-5599.
4. Porter AL, Garner J, Newman NC, et al. National nanotechnology research prominence. *Technol Anal Strateg Manag*. 2019;31(1):25-39.
5. Sargent JF Jr. *Nanotechnology: A Policy Primer*. Washington DC: Congressional Research Service; 2016. Accessed July 11, 2022. <https://sgp.fas.org/crs/misc/RL34511.pdf>
6. European Commission. *Advanced Technologies for Industry: Report on Technology Trends and Technology Adoption – Final Report*. Luxembourg: Publications Office of the European Union; 2021 Accessed July 22, 2022. <https://ati.ec.europa.eu/sites/default/files/2021-10/ATI%20Final%20Report%20on%20technology%20trends%20and%20technology%20adoption.pdf>
7. National Science and Technology Council. *National Nanotechnology Initiative: The Initiative and its Implementation Plan*. Washington DC: Office of Science and Technology Policy; 2000. Accessed August 4, 2022. https://www.nano.gov/sites/default/files/pub_resource/nni_implementation_plan_2000.pdf
8. Subcommittee on Nanoscale Science, Engineering, and Technology. *The National Nanotechnology Initiative Supplement to the President's 2022 Budget*. Washington, DC: National Science and Technology Council; 2022. Accessed July 22, 2022. https://www.nano.gov/sites/default/files/pub_resource/NNI-FY22-Budget-Supplement.pdf
9. Roco MC, Hersam MC, Mirkin CA. *Nanotechnology Research Directions for Societal Needs in 2020: Retrospective and Outlook*. New York: Springer; 2011.
10. Peplow M. Graphene: the quest for supercarbon. *Nature*. 2013;503(7476):327-329.
11. Graphene Flagship. Funding. Accessed August 2, 2022. <https://graphene-flagship.eu/research/funding/>
12. KPMG. *JSC RUSNANO International Financial Reporting Standards Consolidated Financial Statements and Independent Auditor's Report*. Moscow: KPMG; 2018. Accessed August 4, 2022. https://www.rusnano.com/upload/normativedocs/RUSNANO_IFRS_2018_ENG.pdf
13. Zvonareva O. Risky economies: innovation of medical devices in Russia. In: Zvonareva O. *Health, Technologies, and Politics in Post-Soviet Settings: Navigating Uncertainties*. London: Palgrave Macmillan; 2018:89-116.
14. Qiu J. Nanotechnology development in China: challenges and opportunities. *Natl Sci Rev*. 2016;3(1):148-152.
15. O'Meara S. Small science grows large in new hands. *Nature*. 2018;564(7735):S65-S66.
16. *Data in Brief*. Accessed September 19, 2022. <https://www.sciencedirect.com/journal/data-in-brief>
17. *Chemical Data Collections*. Accessed September 19, 2022. <https://www.sciencedirect.com/journal/chemical-data-collections>
18. Bai X, Liu F, Liu Y, et al. Toward a systematic exploration of nano-bio interactions. *Toxicol Appl Pharmacol*. 2017;323:66-73.
19. NBI Knowledgebase. Nanomaterial–Biological Interactions Knowledgebase. Accessed December 17, 2019. <http://nbi.oregonstate.edu/>
20. National Cancer Institute Center for Biomedical Informatics and Information Technology. caNanoLab. Accessed September 19, 2022. <https://cananolab.nci.nih.gov/caNanoLab/>
21. The Nanodatabase. About us. Accessed July 22, 2022. <https://nanodb.dk/en/about-us/>
22. Ostraat ML, Mills KC, Guzan KA, Murry D. The Nanomaterial Registry: facilitating the sharing and analysis of data in the diverse nanomaterial community. *Int J Nanomed*. 2013;8:7-13.
23. Park HG, Yeo MK. Nanomaterial regulatory policy for human health and environment. *Mol Cell Toxicol*. 2016;12(3):223-236.
24. Justo-Hanani R, Dayan T. European risk governance of nanotechnology: explaining the emerging regulatory policy. *Res Policy*. 2015;44(8):1527-1536.
25. Trump BD, Keisler JM, Galaisi SE, Palma-Oliveira JM, Linkov I. Safety-by-design as a governance problem. *Nano Today*. 2020;35:100989.
26. Stone V, Führ M, Feindt PH, et al. The essential elements of a risk governance framework for current and future nanotechnologies. *Risk Anal*. 2018;38(7):1321-1331.
27. United States Environmental Protection Agency. Control of nanoscale materials under the Toxic Substances Control Act. Accessed September 19, 2022. <https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/control-nanoscale-materials-under>
28. Government of Canada. Canada–United States Regulatory Cooperation Council initiative on chemicals management. Updated October 6, 2017. Accessed September 19, 2022. <https://www.canada.ca/en/health-canada/services/chemical-substances/chemicals-management-plan/canada-united-states-regulatory-cooperation-council.html>
29. Organisation for Economic Co-operation and Development. Our global reach. Accessed August 4, 2022. <https://www.oecd.org/about/members-and-partners/>
30. International Organization for Standardization (ISO). ISO/TC 229 – Nanotechnologies. Accessed September 19, 2022. <https://www.iso.org/cms/render/live/en/sites/isoorg/contents/data/committee/38/19/381983.html>
31. ASTM International. Committee E56 on nanotechnology. Accessed September 19, 2022. <https://www.astm.org/COMMITTEE/E56.htm>
32. ASTM International. Committee E56 officers and staff support. Accessed August 4, 2022. <https://www.astm.org/get-involved/technical-committees/committee-e56/officers-e56>
33. Bundesanstalt für Materialforschung und -prüfung. About us. Accessed September 19, 2022. <https://www.bam.de/Navigation/EN/About-us/about-us.html>
34. International Electrotechnical Commission. TC 113 Nanotechnology for electrotechnical products and systems: TC 113 scope. Accessed September 19, 2022. https://www.iec.ch/dyn/www/?p=103:7:16064114749424:::FSP_ORG_ID,FSP_LANG_ID:1315,25
35. International Electrotechnical Commission. TC 113 Nanotechnology for electrotechnical products and systems: TC 113 structure. Accessed August 4, 2022. https://www.iec.ch/dyn/www/?p=103:29:615878171854764:::FSP_ORG_ID,FSP_LANG_ID:1315,25#3

36. IEEE NANO. IEEE Nanotechnology Council Advancing Nanotech for Humanity: about NTC. Accessed September 19, 2022. <https://ieeenano.org/>
37. IEEE NANO. IEEE Nanotechnology Council Advancing Nanotech for Humanity: officers. Accessed August 4, 2022. <https://ieeenano.org/officers>
38. American National Standards Institute (ANSI). ANSI Nanotechnology Standards Panel (ANSI-NSP). Accessed August 8, 2022. <https://www.ansi.org/standards-coordination/collaboratives-activities/nanotechnology-panel>
39. United States Environmental Protection Agency. Research on nanomaterials. Updated June 1, 2022. Accessed September 19, 2022. <https://www.epa.gov/chemical-research/research-nanomaterials>
40. United States Environmental Protection Agency Office of Research and Development. Nanotechnology & nanomaterials research. Accessed August 8, 2022. <https://www.epa.gov/sites/default/files/2013-12/documents/nanotechnology-fact-sheet.pdf>
41. United States Environmental Protection Agency. Summary of the Toxic Substances Control Act. Updated October 22, 2021. Accessed September 19, 2022. <https://www.epa.gov/laws-regulations/summary-toxic-substances-control-act>
42. United States Environmental Protection Agency Office of Land and Emergency Management. Technical fact sheet – nanomaterials. Published November 2017. Accessed August 8, 2022. https://www.epa.gov/sites/default/files/2014-03/documents/ffrrofactsheet_emergingcontaminant_nanomaterials_jan2014_final.pdf
43. United States Environmental Protection Agency. Safe Drinking Water Act (SDWA). Updated July 14, 2022. Accessed September 19, 2022. <https://www.epa.gov/sdwa>
44. United States Environmental Protection Agency. Summary of the Federal Insecticide, Fungicide, and Rodenticide Act. Last updated September 12, 2022. Accessed September 19, 2022. <https://www.epa.gov/laws-regulations/summary-federal-insecticide-fungicide-and-rodenticide-act>
45. United States Environmental Protection Agency. Summary of the Comprehensive Environmental Response, Compensation, and Liability Act (Superfund). Updated September 12, 2022. Accessed September 19, 2022. <https://www.epa.gov/laws-regulations/summary-comprehensive-environmental-response-compensation-and-liability-act>
46. United States Environmental Protection Agency. Summary of the Resource Conservation and Recovery Act. Updated September 12, 2022. Accessed September 19, 2022. <https://www.epa.gov/laws-regulations/summary-resource-conservation-and-recovery-act>
47. United States Environmental Protection Agency. Summary of the Clean Water Act. Updated July 6, 2022. Accessed September 19, 2022. <https://www.epa.gov/laws-regulations/summary-clean-water-act>
48. United States Environmental Protection Agency. Summary of the Clean Air Act. Updated September 12, 2022. Accessed September 19, 2022. <https://www.epa.gov/laws-regulations/summary-clean-air-act>
49. US Food and Drug Administration. Nanotechnology Task Force. Updated February 23, 2021. Accessed August 8, 2022. <https://www.fda.gov/science-research/nanotechnology-programs-fda/nanotechnology-task-force>
50. US Food and Drug Administration. Center for Drug Evaluation and Research | CDER. Updated June 21, 2022. Accessed September 19, 2022. <https://www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder>
51. US Food and Drug Administration. Center for Biologics Evaluation and Research (CBER). Updated June 29, 2022. Accessed September 19, 2022. <https://www.fda.gov/about-fda/fda-organization/center-biologics-evaluation-and-research-cber>
52. US Food and Drug Administration. Center for Devices and Radiological Health. Updated February 3, 2022. Accessed September 19, 2022. <https://www.fda.gov/about-fda/fda-organization/center-devices-and-radiological-health>
53. National Institute for Occupational Safety and Health. Nanotechnology. Updated March 27, 2020. Accessed September 19, 2022. <https://www.cdc.gov/niosh/topics/nanotech/default.html>
54. International Organization for Standardization. Members. Accessed August 4, 2022. <https://www.iso.org/members.html>
55. International Electrotechnical Commission. National committees. Accessed August 4, 2022. <https://www.iec.ch/national-committees#nclist>
56. IEEE NANO. IEEE Nanotechnology Council Advancing Nanotech for Humanity: chapters & regional activities. Accessed August 8, 2022. <https://ieeenano.org/technical-activities/chapters>
57. Ridge S. A regulatory framework for nanotechnology. *Homel Secur Aff*. 2018;16.
58. Helmus MN. The need for rules and regulations. *Nat Nanotechnol*. 2007;2(6):333-334.
59. Faunce T, Watal A. Nanosilver and global public health: international regulatory issues. *Nanomed*. 2010;5(4):617-632.
60. Sarmento B. Have nanomedicines progressed as much as we'd hoped for in drug discovery and development? *Expert Opin Drug Discov*. 2019;14(8):723-725.
61. Taylor AA, Schierz A, Freeman EL. New nanomaterial regulations require detailed information from industry. *Exponent Environmental Perspectives Newsletter*. Published June 2017. Accessed June 13, 2022. <https://www.exponent.com/-/media/news-events-alerts/alerts/2017/06/new-nanomaterial-regulations/new-nanomaterial-regulations-require-detailed-information-from-industry.pdf>
62. Hua S, de Matos MBC, Metselaar JM, Storm G. Current trends and challenges in the clinical translation of nanoparticulate nanomedicines: pathways for translational development and commercialization. *Front Pharmacol*. 2018; 9:790.
63. Heller DA, Jena PV, Pasquali M, et al. Banning carbon nanotubes would be scientifically unjustified and damaging to innovation. *Nat Nanotechnol*. 2020;15(3):164-166.
64. Richman EK, Hutchison JE. The nanomaterial characterization bottleneck. *ACS Nano*. 2009;3(9):2441-2446.
65. Trump BD, Galaitis SE, Appleton E, et al. Building biosecurity for synthetic biology. *Mol Syst Biol*. 2020;16(7): e9723.
66. Stemerding D, Betten W, Rerimassie V, Robaey Z, Kupper F. Future making and responsible governance of innovation in synthetic biology. *Futures*. 2019;109:213-226.

67. Su H, Wang Y, Gu Y, Bowman L, Zhao J, Ding M. Potential applications and human biosafety of nanomaterials used in nanomedicine. *J Appl Toxicol.* 2018;38(1):3-24.
68. Trump BD, Florin MV, Perkins E, Linkov I, eds. *Emerging Threats of Synthetic Biology and Biotechnology: Addressing Security and Resilience Issues.* Dordrecht, Netherlands: Springer Nature, 2021.
69. Linkov I, Trump BD, Anklam E, et al. Comparative, collaborative, and integrative risk governance for emerging technologies. *Environ Syst Decis.* 2018;38(2):170-176.
70. Cha C, Shin SR, Annabi N, Dokmeci MR, Khademhosseini A. Carbon-based nanomaterials: multi-functional materials for biomedical engineering. *ACS Nano.* 2013;7(4):2891-2897.
71. Loh KP, Ho D, Chiu GNC, Leong DT, Pastorin G, Chow EK-H. Clinical applications of carbon nanomaterials in diagnostics and therapy. *Adv Mater.* 2018;30(47):e1802368.
72. d'Amora M, Giordani S. Carbon Nanomaterials for Nanomedicine. In: Ciofani G, ed. *Smart Nanoparticles for Biomedicine.* Amsterdam: Elsevier, 2019;103-113.
73. Cui X, Xu S, Wang X, Chen C. The nano-bio interaction and biomedical applications of carbon nanomaterials. *Carbon.* 2018;138:436-450.
74. Durairaj S, Sidhureddy B, Cirone J, Chen A. Nanomaterials-based electrochemical sensors for in vitro and in vivo analyses of neurotransmitters. *Appl Sci.* 2018;8(9):1504.
75. Rahmati M, Mozafari M. Biological response to carbon-family nanomaterials: interactions at the nano-bio interface. *Front Bioeng Biotechnol.* 2019;7:4.
76. Singh D, Singh S, Sahu J, Srivastava S, Singh MR. Ceramic nanoparticles: recompense, cellular uptake and toxicity concerns. *Artif Cells Nanomedicine Biotechnol.* 2016;44(1):401-409.
77. Baino F. Bioactive glasses and glass-ceramics for ophthalmological applications. In: Kaur G, ed. *Biomedical, Therapeutic and Clinical Applications of Bioactive Glasses.* Duxford, UK: Woodhead Publishing; 2019:357-382.
78. Madhumathi K, Rubaiya Y, Doble M, Venkateswari R, Sampath Kumar TS. Antibacterial, anti-inflammatory, and bone-regenerative dual-drug-loaded calcium phosphate nanocarriers—in vitro and in vivo studies. *Drug Deliv Transl Res.* 2018;8(5):1066-1077.
79. Du X, Fu S, Zhu Y. 3D printing of ceramic-based scaffolds for bone tissue engineering: an overview. *J Mater Chem B.* 2018;6(27):4397-4412.
80. Anderson SD, Gwenin VV, Gwenin CD. Magnetic functionalized nanoparticles for biomedical, drug delivery and imaging applications. *Nanoscale Res Lett.* 2019;14:188.
81. Zhao X, Zhou L, Rajoka MSR, et al. Fungal silver nanoparticles: synthesis, application and challenges. *Crit Rev Biotechnol.* 2018;38(6):817-835.
82. Evans ER, Bugga P, Asthana V, Drezek R. Metallic nanoparticles for cancer immunotherapy. *Mater Today.* 2018;21(6):673-685.
83. Singh P, Pandit S, Mokkapat VRSS, Garg A, Ravikumar V, Mijakovic I. Gold nanoparticles in diagnostics and therapeutics for human cancer. *Int J Mol Sci.* 2018;19(7):1979.
84. Thota S, Crans DC, eds. *Metal Nanoparticles: Synthesis and Applications in Pharmaceutical Sciences.* Weinheim, Germany: Wiley-VCH; 2018.
85. Granada-Ramírez DA, Arias-Cerón JS, Rodríguez-Fragoso P, et al. Quantum dots for biomedical applications. In: Narayan R, ed. *Nanobiomaterials: Nanostructured Materials for Biomedical Applications.* Duxford, UK: Woodhead Publishing; 2018:411-436.
86. Jayakumar R, Menon D, Manzoor K, Nair SV, Tamura H. Biomedical applications of chitin and chitosan based nanomaterials—a short review. *Carbohydr Polym.* 2010;82(2):227-232.
87. Sun H, Hong Y, Xi Y, Zou Y, Gao J, Du J. Synthesis, self-assembly, and biomedical applications of antimicrobial peptide-polymer conjugates. *Biomacromolecules.* 2018;19(6):1701-1720.
88. Kalantari K, Affi A, Jahangirian H, Webster TJ. Biomedical applications of chitosan electrospun nanofibers as a green polymer – review. *Carbohydr Polym.* 2019;207:588-600.
89. Aguilar MR, San Román J, eds. *Smart Polymers and Their Applications.* 2nd ed. Duxford, UK: Woodhead Publishing, 2019.
90. Kirillova A, Ionov L. Shape-changing polymers for biomedical applications. *J Mater Chem B.* 2019;7(10):1597-1624.
91. Singh G, Faruk A, Bedi PMS. Technology overview and current biomedical application of polymeric nanoparticles. *J Drug Deliv Ther.* 2018;8(6):285-295.
92. Spicer CD, Jumeaux C, Gupta B, Stevens MM. Peptide and protein nanoparticle conjugates: versatile platforms for biomedical applications. *Chem Soc Rev.* 2018;47(10):3574-3620.
93. Khan HA, Sakharkar MK, Nayak A, Kishore U, Khan A. Nanoparticles for biomedical applications: an overview. In: Narayan R, ed. *Nanobiomaterials: Nanostructured Materials for Biomedical Applications.* Duxford, UK: Woodhead Publishing; 2018:357-384.
94. Ball RL, Hajj KA, Vizelman J, Bajaj P, Whitehead KA. Lipid nanoparticle formulations for enhanced co-delivery of siRNA and mRNA. *Nano Lett.* 2018;18(6):3814-3822.
95. Zahin N, Anwar R, Tewari D, et al. Nanoparticles and its biomedical applications in health and diseases: special focus on drug delivery. *Environ Sci Pollut Res Int.* 2020;27(16):19151-19168.
96. Wallyn J, Anton N, Akram S, Vandamme TF. Biomedical imaging: principles, technologies, clinical aspects, contrast agents, limitations and future trends in nanomedicines. *Pharm Res.* 2019;36(6):78.
97. Agrawal G, Agrawal R. Janus nanoparticles: recent advances in their interfacial and biomedical applications. *ACS Appl Nano Mater.* 2019;2(4):1738-1757.
98. Fan X, Yang J, Loh XJ, Li Z. Polymeric Janus nanoparticles: recent advances in synthetic strategies, materials properties, and applications. *Macromol Rapid Commun.* 2019;40(5):e1800203.
99. Jeevanandam J, Barhoum A, Chan YS, Dufresne A, Danquah MK. Review on nanoparticles and nanostructured materials: history, sources, toxicity and regulations. *Beilstein J Nanotechnol.* 2018;9:1050-1074.
100. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol.* 2015;33(9):941-951.

101. Ashby MF, Ferreira PJ, Schodek DL. The design context. In: Ashby MF, Ferreira PJ, Schodek DL, eds. *Nanomaterials, Nanotechnologies and Design*. Boston: Butterworth-Heinemann; 2009:41-86.
102. Shen Z, Nieh MP, Li Y. Decorating nanoparticle surface for targeted drug delivery: opportunities and challenges. *Polymers (Basel)*. 2016;8(3):83.
103. Kluender EJ, Hedrick JL, Brown KA, et al. Catalyst discovery through megalibraries of nanomaterials. *Proc Natl Acad Sci U S A*. 2019;116(1):40-45.
104. Salley D, Keenan G, Grizou J, Sharma A, Martín S, Cronin L. A nanomaterials discovery robot for the Darwinian evolution of shape programmable gold nanoparticles. *Nat Commun*. 2020;11(1):2771.
105. Lambert B, Gillen AJ, Schuergers N, Wu S-J, Boghossian AA. Directed evolution of the optoelectronic properties of synthetic nanomaterials. *Chem Commun (Camb)*. 2019;55(22):3239-3242.
106. Sago CD, Lokugamage MP, Islam FZ, Krupczak BR, Sato M, Dahlman JE. Nanoparticles that deliver RNA to bone marrow identified by in vivo directed evolution. *J Am Chem Soc*. 2018;140(49):17095-17105.
107. Chen P-C, Liu X, Hedrick JL, et al. Polyelemental nanoparticle libraries. *Science*. 2016;352(6293):1565-1569.
108. Bourquin J, Milosevic A, Hauser D, et al. Biodistribution, clearance, and long-term fate of clinically relevant nanomaterials. *Adv Mater*. 2018;30(19):e1704307.
109. Singh AV, Laux P, Luch A, et al. Review of emerging concepts in nanotoxicology: opportunities and challenges for safer nanomaterial design. *Toxicol Mech Methods*. 2019;29(5):378-387.
110. Navya PN, Daima HK. Rational engineering of physicochemical properties of nanomaterials for biomedical applications with nanotoxicological perspectives. *Nano Conver*. 2016;3:1.
111. Holban A-M, Grumezescu AM, eds. *Materials for Biomedical Engineering: Nanomaterials-Based Drug Delivery*. Amsterdam: Elsevier; 2019.
112. Rizvi SAA, Saleh AM. Applications of nanoparticle systems in drug delivery technology. *Saudi Pharm J*. 2018;26(1):64-70.
113. Zhong H, Chan G, Hu Y, Hu H, Ouyang D. A comprehensive map of FDA-approved pharmaceutical products. *Pharmaceutics*. 2018;10(4):263.
114. Aguilar ZP. Targeted drug delivery. In: Aguilar ZP. *Nanomaterials for Medical Applications*. Amsterdam: Elsevier; 2013:181-234.
115. Suk JS, Xu Q, Kim N, Hanes J, Ensign LM. PEGylation as a strategy for improving nanoparticle-based drug and gene delivery. *Adv Drug Deliv Rev*. 2016;99(Pt A):28-51.
116. Van Haute D, Berlin JM. Challenges in realizing selectivity for nanoparticle biodistribution and clearance: lessons from gold nanoparticles. *Ther Deliv*. 2017;8(9):763-774.
117. Rabiee M, Rabiee N, Salarian R, Rabiee G. *Introduction to Nanomaterials in Medicine*. San Rafael, CA: Morgan & Claypool Publishers; 2019.
118. Yan L, Zhao F, Wang J, Zu Y, Gu Z, Zhao Y. A safe-by-design strategy towards safer nanomaterials in nanomedicines. *Adv Mater*. 2019;31(45):e1805391.
119. Arnold AM, Holt BD, Tang C, Sydlík SA. Phosphate modified graphene oxide: long-term biodegradation and cytocompatibility. *Carbon*. 2019;154:342-349.
120. Chen F, Alphonse M, Liu Q. Strategies for nonviral nanoparticle-based delivery of CRISPR/Cas9 therapeutics. *Wiley Interdiscip Rev Nanomed Nanobiotechnol*. 2020;12(3):e1609.
121. Fajrial AK, He QQ, Wirusanti NI, Slansky JE, Ding X. A review of emerging physical transfection methods for CRISPR/Cas9-mediated gene editing. *Theranostics*. 2020;10(12):5532-5549.
122. Givens BE, Naguib YW, Geary SM, Devor EJ, Salem AK. Nanoparticle-based delivery of CRISPR/Cas9 genome-editing therapeutics. *AAPS J*. 2018;20(6):108.
123. Rahimi H, Salehiabar M, Charmi J, et al. Harnessing nanoparticles for the efficient delivery of the CRISPR/Cas9 system. *Nano Today*. 2020;34:100895.
124. Cheng Q, Wei T, Farbiak L, Johnson LT, Dilliard SA, Siegwart DJ. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR-Cas gene editing. *Nat Nanotechnol*. 2020;15(4):313-320.
125. Aghamiri S, Talaei S, Ghavidel AA, et al. Nanoparticles-mediated CRISPR/Cas9 delivery: recent advances in cancer treatment. *J Drug Deliv Sci Technol*. 2020;56:101533.
126. Rosenblum D, Gutkin A, Kedmi R, et al. CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy. *Sci Adv*. 2020;6(47):eabc9450.
127. Ricciardi AS, Bahal R, Farrelly JS, et al. In utero nanoparticle delivery for site-specific genome editing. *Nat Commun*. 2018;9:2481.
128. Varma LT, Singh N, Gorain B, et al. Recent advances in self-assembled nanoparticles for drug delivery. *Curr Drug Deliv*. 2020;17(4):279-291.
129. Gisbert-Garzarán M, Berkman JC, Giasafaki D, et al. Engineered pH-responsive mesoporous carbon nanoparticles for drug delivery. *ACS Appl Mater Interfaces*. 2020;12(13):14946-14957.
130. Nagaraju GP, Srivani G, Dariya B, et al. Nanoparticles guided drug delivery and imaging in gastric cancer. *Semin Cancer Biol*. 2021;69:69-76.
131. Hasnain MS, Nayak AK, Kurakula M, Hoda MN. Alginate nanoparticles in drug delivery. In: Nayak AK, Hasnain MS, eds. *Alginates in Drug Delivery*. London: Academic Press; 2020:129-152.
132. Begines B, Ortiz T, Pérez-Aranda M, et al. Polymeric nanoparticles for drug delivery: recent developments and future prospects. *Nanomaterials (Basel)*. 2020;10(7):1403.
133. Alyassin Y, Sayed EG, Mehta P, et al. Application of mesoporous silica nanoparticles as drug delivery carriers for chemotherapeutic agents. *Drug Discov Today*. 2020;25(8):1513-1520.
134. Chung YH, Cai H, Steinmetz NF. Viral Nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications. *Adv Drug Deliv Rev*. 2020;156:214-235.
135. Manzano M, Vallet-Regí M. Mesoporous silica nanoparticles for drug delivery. *Adv Funct Mater*. 2020;30(2):1902634.
136. Åslund AKO, Berg S, Hak S, et al. Nanoparticle delivery to the brain—by focused ultrasound and self-assembled nanoparticle-stabilized microbubbles. *J Control Release*. 2015;220(Pt A):287-294.
137. Zhao X, Shang T, Zhang X, Ye T, Wang D, Rei L. Passage of magnetic tat-conjugated Fe₃O₄@SiO₂ nanoparticles across in vitro blood-brain barrier. *Nanoscale Res Lett*. 2016;11:451.

138. Ohta S, Kikuchi E, Ishijima A, Azuma T, Sakuma I, Ito T. Investigating the optimum size of nanoparticles for their delivery into the brain assisted by focused ultrasound-induced blood–brain barrier opening. *Sci Rep.* 2020;10:18220.
139. Kaushik A, Yndart A, Atluri V, et al. Magnetically guided non-invasive CRISPR-Cas9/gRNA delivery across blood-brain barrier to eradicate latent HIV-1 infection. *Sci Rep.* 2019;9:3928.
140. Teleanu DM, Chircov C, Grumezescu AM, Volceanov A, Teleanu RI. Blood-brain delivery methods using nanotechnology. *Pharmaceutics.* 2018;10(4):269.
141. Bors LA, Erdő F. Overcoming the blood–brain barrier: challenges and tricks for CNS drug delivery. *Sci Pharm.* 2019;87(1):6.
142. Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. *Acta Pharm Sin B.* 2016;6(4):268–286.
143. Oescheger F, Jenal U. Misuse potential and biosecurity in life sciences research. *Swiss Academies Rep.* 2017;12:3.
144. Kosal M. The security implications of nanotechnology. *Bull At Sci.* 2010;66(4):58–69.
145. Rodriguez PL, Harada T, Christian DA, Pantano DA, Tsai RK, Discher DE. Minimal “self” peptides that inhibit phagocytic clearance and enhance delivery of nanoparticles. *Science.* 2013;339(6122):971–975.
146. NovaVax. Pipeline—creating tomorrow’s vaccines today. Accessed September 19, 2022. <https://www.novavax.com/our-pipeline>
147. Shinde V, Bhikha S, Hoosain Z, et al. A. Efficacy of NVX-CoV2373 Covid-19 vaccine against the B.1.351 variant. *N Engl J Med.* 2021;384(20):1899–1909.
148. White BD, Duan C, Townley HE. Nanoparticle activation methods in cancer treatment. *Biomolecules.* 2019;9(5):202.
149. Kaur P, Aliru ML, Chadha AS, Asea A, Krishnan S. Hyperthermia using nanoparticles—promises and pitfalls. *Int J Hyperth.* 2016;32(1):76–88.
150. Ma Y, Bao J, Zhang Y, et al. Mammalian near-infrared image vision through injectable and self-powered retinal nanoantennae. *Cell.* 2019;177(2):243–255.e15.
151. Bar-Ilan University. Bar-Ilan University: researchers invent nano-drops that improve nearsightedness and farsightedness. *PRNewswire.* March 8, 2018. Accessed September 20, 2022. <https://www.prnewswire.com/news-releases/bar-ilan-university—researchers-invent-nano-drops-that-improve-nearsightedness-and-farsightedness-300610963.html>
152. Mannoor MS, Jiang Z, James T, et al. 3D printed bionic ears. *Nano Lett.* 2013;13(6):2634–2639.
153. Schumann C, Nguyen DX, Norgard M, et al. Increasing lean muscle mass in mice via nanoparticle-mediated hepatic delivery of follistatin mRNA. *Theranostics.* 2018;8(19):5276–5288.
154. Raimondo TM, Mooney DJ. Functional muscle recovery with nanoparticle-directed M2 macrophage polarization in mice. *Proc Natl Acad Sci U S A.* 2018;115(42):10648–10653.
155. Leong J, Hong YT, Wu YF, et al. Surface tethering of inflammation-modulatory nanostimulators to stem cells for ischemic muscle repair. *ACS Nano.* 2020;14(5):5298–5313.
156. Marino A, Arai S, Hou Y, et al. Gold nanoshell-mediated remote myotube activation. *ACS Nano.* 2017;11(3):2494–2508.
157. Edelman BJ, Meng J, Suma D, et al. Noninvasive neuroimaging enhances continuous neural tracking for robotic device control. *Sci Robot.* 2019;4(31):eaaw6844.
158. Neuralink. Engineering with the brain. Accessed September 20, 2022. <https://neuralink.com/applications/>
159. Kim Y, Meade SM, Chen K, et al. Nano-architectural approaches for improved intracortical interface technologies. *Front Neurosci.* 2018;12:456.
160. Reardon S. Global summit reveals divergent views on human gene editing. *Nature.* 2015;528(7581):173.
161. Liu S. Legal reflections on the case of genome-edited babies. *Glob Health Res Policy.* 2020;5:24.
162. Raposo VL. The first Chinese edited babies: a leap of faith in science. *JBRA Assist Reprod.* 2019;23(3):197–199.
163. Wang H, Yang H. Gene-edited babies: what went wrong and what could go wrong. *PLoS Biol.* 2019;17(4):e3000224.
164. World Health Organization (WHO). *WHO Expert Advisory Committee on Developing Global Standards for Governance and Oversight of Human Genome Editing: Report of the Sixth Meeting.* Geneva: WHO; 2019:11. Accessed July 11, 2022. <https://www.who.int/publications/i/item/who-expert-advisory-committee-on-developing-global-standards-for-governance-and-oversight-of-human-genome-editing-report-of-the-sixth-meeting>
165. *NanoEthics.* Accessed May 3, 2022. <https://www.springer.com/journal/11569>
166. Zolnik BS, González-Fernández Á, Sadrieh N, Dobrovolskaia MA. Nanoparticles and the immune system. *Endocrinol.* 2010;151(2):458–465.
167. Kandel ER. The molecular biology of memory: cAMP, PKA, CRE, CREB-1, CREB-2, and CPEB. *Mol Brain.* 2012;5:14.
168. Marx G, Gilon C. The molecular basis of memory. *ACS Chem Neurosci.* 2012;3(8):633–642.
169. Ai L, Tan T, Tang Y, et al. Endogenous formaldehyde is a memory-related molecule in mice and humans. *Commun Biol.* 2019;2:446.
170. Kassick AJ, Wu M, Luengas D, et al. Covalently loaded naloxone nanoparticles as a long-acting medical countermeasure to opioid poisoning. *ACS Pharmacol Transl Sci.* 2021;4(5):1654–1664.
171. Kovaliov M, Li S, Korkmaz E, et al. Extended-release of opioids using fentanyl-based polymeric nanoparticles for enhanced pain management. *RSC Adv.* 2017;7(76):47904–47912.
172. Jimenez-Vargas NN, Gong J, Wisdom MJ, et al. Endosomal signaling of delta opioid receptors is an endogenous mechanism and therapeutic target for relief from inflammatory pain. *Proc Natl Acad Sci U S A.* 2020;117(26):15281–15292.
173. Hempel G, Janosek DB, Raziano DB. Hacking humans: a case study and analysis of vulnerabilities in the advancing medical device landscape. *Cyber Secur Peer-Rev J.* 2020;3(4):351–362.
174. Pycroft L, Aziz TZ. Security of implantable medical devices with wireless connections: the dangers of cyber-attacks. *Expert Rev Med Devices.* 2018;15(6):403–406.
175. King NMP, Bishop CE. How should physicians help patients understand unknowns of nanoparticle-based medicines? *AMA J Ethics.* 2019;21(4):324–331.

176. Uskoković V. Nanomedicine for the poor: a lost cause or an idea whose time has yet to come? *Nanomedicine (Lond)*. 2021;16(14):1203-1218.
177. Bundschuh M, Filser J, Lüderwald S, et al. Nanoparticles in the environment: where do we come from, where do we go to? *Environ Sci Eur*. 2018;30(1):6.
178. Zou Q. Nanoparticles in automotive applications. In: Wang QJ, Chung YW, eds. *Encyclopedia of Tribology*. Boston: Springer; 2013:2376-2381.
179. Mariappan N. Recent trends in nanotechnology applications in surgical specialties and orthopedic surgery. *Biomed Pharmacol J*. 2019;12(3):1095-1127.
180. Singh T, Shukla S, Kumar P, Wahla V, Bajpai VK. Application of nanotechnology in food science: perception and overview. *Front Microbiol*. 2017;8:1501.
181. Manaia EB, Kaminski RCK, Corrêa MA, Chiavacci LA. Inorganic UV filters. *Braz J Pharm Sci*. 2013;49(2):201-209.
182. Schilling K, Bradford B, Castelli D, et al. Human safety review of “nano” titanium dioxide and zinc oxide. *Photochem Photobiol Sci*. 2010;9(4):495-509.
183. Asztemborska M, Jakubiak M, Stęborowski R, Chajduk E, Bystrzejewska-Piotrowska G. Titanium dioxide nanoparticle circulation in an aquatic ecosystem. *Water Air Soil Pollut*. 2018;229(6):208.
184. Baranowska-Wójcik E, Szwajgier D, Oleszczuk P, Winiarska-Mieczan A. Effects of titanium dioxide nanoparticles exposure on human health—a review. *Biol Trace Elem Res*. 2020;193(1):118-129.
185. Guo Z, Martucci NJ, Moreno-Olivas F, Tako E, Mahler GJ. Titanium dioxide nanoparticle ingestion alters nutrient absorption in an *in vitro* model of the small intestine. *NanoImpact*. 2017;5:70-82.
186. Ziental D, Czarczynska-Goslinska B, Mlynarczyk DT, et al. Titanium dioxide nanoparticles: prospects and applications in medicine. *Nanomaterials (Basel)*. 2020;10(2):387.
187. Wiesmann N, Tremel W, Brieger J. Zinc oxide nanoparticles for therapeutic purposes in cancer medicine. *J Mater Chem B*. 2020;8(23):4973-4989.
188. Greish K, Alqahtani AA, Alotaibi AF, et al. The effect of silver nanoparticles on learning, memory and social interaction in BALB/C mice. *Int J Environ Res Public Health*. 2019;16(1):148.
189. Ferdous Z, Nemmar A. Health impact of silver nanoparticles: a review of the biodistribution and toxicity following various routes of exposure. *Int J Mol Sci*. 2020;21(7):2375.
190. Vazquez-Muñoz R, Borrego B, Juárez-Moreno K, et al. Toxicity of silver nanoparticles in biological systems: does the complexity of biological systems matter? *Toxicol Lett*. 2017;276:11-20.
191. Mao BH, Chen ZY, Wang YJ, Yan SJ. Silver nanoparticles have lethal and sublethal adverse effects on development and longevity by inducing ROS-mediated stress responses. *Sci Rep*. 2018;8:2445.
192. US Department of Food and Agriculture Foreign Agricultural Service. France: France bans titanium dioxide in food products by January 2020. Published May 8, 2019. Accessed June 10, 2022. <https://www.fas.usda.gov/data/france-france-bans-titanium-dioxide-food-products-january-2020>
193. Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. Accessed July 22, 2022. <https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A02008R1272-20220301>
194. Canadian General Standards Board (CGSB). *Organic Production Systems: Permitted Substances Lists*. Ottawa: CGSB; 2021. Accessed July 11, 2022. https://publications.gc.ca/collections/collection_2020/ongc-cgsb/P29-32-311-2020-eng.pdf

Manuscript received January 24, 2022;
 revision returned May 6, 2022;
 accepted for publication May 16, 2022.

Address correspondence to:
 Kristin M. Omberg, PhD
 Group Leader
 National Security Directorate
 Pacific Northwest National Laboratory
 P.O. Box 999, MSIN P7-50
 Richland, WA 99354
 Email: kristin.omberg@pnnl.gov